NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Cardurion Pharmaceuticals

Cardurion Pharmaceuticals

Private
Burlington, MassachusettsHealthcare & Life Scienceshttps://cardurion.com/

Last Round

Series B

Jul 16, 2024

Total Funding Raised

$631.8M

Company Overview

Cardurion Pharmaceuticals is a biotechnology company that develops innovative cardiovascular therapeutics aimed at treating heart diseases and preventing related complications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologycardiovascular diseaseheart failuresmall-molecule therapeuticsPDE9 inhibitordrug discoveryclinical-stage biotechphosphodiesterase inhibitorbiotech pipelineclinical trialscardiac therapybiopharmadrug developmenttherapeutic pipelinemedicinal chemistry

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cardurion Pharmaceuticals Comparables

Compare Cardurion Pharmaceuticals with similar companies based on industry and business-model similarity.

Cardurion Pharmaceuticals comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AnaCardio
77%
Windtree Therapeutics, Inc.
77%
Cytokinetics, Incorporated
72%

Cardurion Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJul 16, 2024
Series A ExtensionDec 30, 2022
Private EquityOct 27, 2021
Series ANov 20, 2019
SeedAug 3, 2017
Seed
Apr 4, 2017

Key People

Founding team and executive leadership

Peter Lawrence

CEO And President

Executive Team

Elizabeth Radcliffe

Chief Financial Officer

Executive Team

Marcia Moore

Chief Operating Officer

Executive Team

Cardurion Pharmaceuticals Investors

Notable investors and investment history

Cardurion Pharmaceuticals investors
InvestorRounds
Owl Rock Capital GroupSeries B
Bain Capital Life SciencesSeries B, Private Equity
Farallon Capital ManagementSeries B
GVSeries B
Digitalis VenturesSeries B
New Enterprise Associates (NEA)Series B
Millennium ManagementSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 20, 2025

    Karen Lewis joins as Chief People Officer.

  • Jan 8, 2025

    Charlotte Newman joins as Chief Business Officer.

Cardurion Pharmaceuticals Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Cardurion Pharmaceuticals Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Cardurion Pharmaceuticals's valuation, stock price, and market status.

Firmographic Details

HeadquartersBurlington, Massachusetts
Employee Range77
Year Founded2017
Last FundingJul 16, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.